Navigation Links
HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
Date:4/21/2009

Collaboration will leverage HUYA's growing Chinese bioscience network

SAN DIEGO, April 21 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.

Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.

"China has an extremely rich pool of drug candidates, which we are able to tap through our extensive network of partners," said Mireille Gingras, PhD, President and CEO of HUYA. "We've been effective in leveraging those relationships to the mutual benefit of our partners in the West and in China, and we're looking forward to a productive collaboration with Abbott."

HUYA's model is based on long-term relationships with its Chinese partners and this provides a continuous source of compounds, unlike a single compound strategy. Once a compound is licensed, the ongoing exchange of expertise and data lowers risk and facilitates rapid and efficient clinical development in both China and the West.

HUYA currently has two clinical stage drugs licensed from China in the therapeutic areas of Cardiovascular and Oncology for development in the West.

HUYA's innovative model benefits partners in the West and China

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China and provides access to those compounds to partners in the West. Likewise, HUYA provides a valuable bridge to Western development for its partners in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its Chinese partners to discuss and design pre-clinical tests and clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"HUYA has forged highly productive relationships with its Chinese partners, which sets up the potential for clinical development and new treatment options in several diseases," said Eric Topol, Chief Academic Officer, Scripps Health, San Diego, CA.

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with four strategic offices in China, a broad Chinese compound portfolio, and a significant number of exclusive agreements with premier Chinese biotech centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.

Contact:

    USA:
    Jan Tuttleman, PhD
    Vice President, Marketing
    HUYA Bioscience International, LLC
    (858) 798-8800
    jtuttleman@huyabio.com

    China:
    Li Zhu, PhD
    VP China Operations
    HUYA Bioscience International, LLC
    86 (21) 51323312

Media Contact:

    Juliet Travis
    (510) 452-3771
    juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Biosciences Launches Next-Generation Protein Characterization System
2. Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution
3. Cell Biosciences Announces Publication in Nature Medicine
4. Cell Biosciences Closes $10 Million Series C Financing
5. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
8. Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
9. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
10. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
11. PURE Bioscience Schedules Second Quarter 2009 Financial Results Conference Call for March 12, 2009 at 1:30 P.M. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... Yorba Linda, Ca (PRWEB) , ... July 17, ... ... highly heterogeneous and are characterized by a wide range of overlapping clinical features. ... pace of discovery in the field of NDD research and testing. , ...
(Date:7/16/2017)... (PRWEB) , ... July 16, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Rocking ... five rocking and waving shaker models (both analog and digital) for laboratory applications ...
(Date:7/14/2017)... ... July 13, 2017 , ... Dr. Joshua Mondlick has ... implants into his practice, Mondlick Perio, in the Phoenix area. Dr. Mondlick ... first and only FDA cleared laser treatment to re-grow bone and with significantly less ...
(Date:7/13/2017)... ... July 13, 2017 , ... ... in Specialty Pharmacy. URAC is the independent leader in promoting healthcare quality through ... comprehensive commitment to quality care, improved processes and better patient outcomes. , ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):